{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T15:20:20Z","timestamp":1784647220489,"version":"3.55.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Heart Fail Rev"],"DOI":"10.1007\/s10741-021-10186-7","type":"journal-article","created":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T23:02:30Z","timestamp":1635807750000},"page":"683-695","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Diabetes and SGLT2-iss inhibitors in patients with heart failure with preserved or mid-range left ventricular ejection fractions"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7045-576X","authenticated-orcid":false,"given":"Andrea","family":"Passantino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1299-1756","authenticated-orcid":false,"given":"Caterina","family":"Rizzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8535-3264","authenticated-orcid":false,"given":"Domenico","family":"Scrutinio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6235-984X","authenticated-orcid":false,"given":"Alberto","family":"Palazzuoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,1]]},"reference":[{"key":"10186_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","volume":"124","author":"HC Kenny","year":"2019","unstructured":"Kenny HC, Abel ED (2019) Heart failure in type 2 diabetes mellitus. Circ Res 124:121\u2013141. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.311371","journal-title":"Circ Res"},{"key":"10186_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/ejhf.679","volume":"19","author":"G Targher","year":"2017","unstructured":"Targher G, Dauriz M, Laroche C, Temporelli PL, Hassanein M, Seferovic et al (2017) ESC-HFA HF Long-Term Registry investigators. In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. Eur J Heart Fail 19:54\u201365. https:\/\/doi.org\/10.1002\/ejhf.679","journal-title":"Eur J Heart Fail"},{"key":"10186_CR3","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS et al (2016) 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Eur Heart J 37:2129\u20132200. https:\/\/doi.org\/10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"key":"10186_CR4","doi-asserted-by":"publisher","unstructured":"Bozkurt B, Coats A, Tsutsui H (2021) Universal definition and classification of heart failure. J Card Fail 7:S1071\u20139164(21)00050\u20136.\u00a0https:\/\/doi.org\/10.1016\/j.cardfail.2021.01.022","DOI":"10.1016\/j.cardfail.2021.01.022"},{"key":"10186_CR5","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","volume":"37","author":"D Fitchett","year":"2016","unstructured":"Fitchett D, Zinman B, Wanner C, Lachin JM, Hantel S, Salsali A et al (2016) Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial. Eur Heart J 37:1526\u20131534. https:\/\/doi.org\/10.1093\/eurheartj\/ehv728","journal-title":"Eur Heart J"},{"key":"10186_CR6","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1161\/CIRCULATIONAHA.118.037778","volume":"139","author":"D Fitchett","year":"2019","unstructured":"Fitchett D, Inzucchi SE, Cannon CP, McGuire DK, Scirica BM, Johansen OE et al (2019) Empagliflozin reduced mortality and hospitalization for heart failure across the spectrum of cardiovascular risk in the EMPA-REG OUTCOME trial. Circulation 139:1384\u20131395. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.037778","journal-title":"Circulation"},{"key":"10186_CR7","doi-asserted-by":"publisher","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, CANVAS Program Collaborative Group et al (2017) Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 377:644\u2013657.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa1611925","DOI":"10.1056\/NEJMoa1611925"},{"key":"10186_CR8","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A et al (2019) Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med 380:347\u2013357. https:\/\/doi.org\/10.1056\/NEJMoa1812389","journal-title":"N Engl J Med"},{"key":"10186_CR9","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","volume":"383","author":"CP Cannon","year":"2020","unstructured":"Cannon CP, Pratley R, Dagogo-Jack S, Mancuso J, Huyck S, Masiukiewicz U et al (2020) Cardiovascular outcomes with Ertugliflozin in type 2 diabetes. N Engl J Med 383:1425\u20131435. https:\/\/doi.org\/10.1056\/NEJMoa2004967","journal-title":"N Engl J Med"},{"key":"10186_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1056\/NEJMoa2030186","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK et al (2021) Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med 384:129\u2013139. https:\/\/doi.org\/10.1056\/NEJMoa2030186","journal-title":"N Engl J Med"},{"key":"10186_CR11","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"10186_CR12","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P et al (2020) Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med 383:1413\u20131424. https:\/\/doi.org\/10.1056\/NEJMoa2022190","journal-title":"N Engl J Med"},{"key":"10186_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2030183","volume":"384","author":"DL Bhatt","year":"2021","unstructured":"Bhatt DL, Szarek M, Steg PG, Cannon CP, Leiter LA, McGuire DK et al (2021) Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med 384:117\u2013128. https:\/\/doi.org\/10.1056\/NEJMoa2030183","journal-title":"N Engl J Med"},{"key":"10186_CR14","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/ejhf.1954","volume":"22","author":"PM Seferovi\u0107","year":"2020","unstructured":"Seferovi\u0107 PM, Fragasso G, Petrie M, Mullens W, Ferrari R, Thum T et al (2020) Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 22:1495\u20131503. https:\/\/doi.org\/10.1002\/ejhf.1954","journal-title":"Eur J Heart Fail"},{"key":"10186_CR15","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1093\/eurheartj\/ehm037","volume":"28","author":"WJ Paulus","year":"2007","unstructured":"Paulus WJ, Tsch\u00f6pe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE et al (2007) Eur Heart J 28:2539\u20132550. https:\/\/doi.org\/10.1093\/eurheartj\/ehm037","journal-title":"Eur Heart J"},{"key":"10186_CR16","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.cjca.2018.02.026","volume":"34","author":"P Meagher","year":"2018","unstructured":"Meagher P, Adam M, Civitarese R, Bugyei-Twum A, Connelly KA (2018) Heart failure with preserved ejection fraction in diabetes: mechanisms and management. Can J Cardiol 34:632\u2013643. https:\/\/doi.org\/10.1016\/j.cjca.2018.02.026","journal-title":"Can J Cardiol"},{"key":"10186_CR17","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jacc.2014.05.030","volume":"64","author":"BR Lindman","year":"2014","unstructured":"Lindman BR, D\u00e1vila-Rom\u00e1n VG, Mann DL, McNulty S, Semigran MJ, Lewis GD et al (2014) Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol 64:541\u2013549. https:\/\/doi.org\/10.1016\/j.jacc.2014.05.030","journal-title":"J Am Coll Cardiol"},{"key":"10186_CR18","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1161\/CIRCULATIONAHA.116.024593","volume":"135","author":"SL Kristensen","year":"2017","unstructured":"Kristensen SL, Mogensen UM, Jhund PS, Petrie MC, Preiss D, Win S et al (2017) Circulation 135:724\u2013735. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.024593","journal-title":"Circulation"},{"key":"10186_CR19","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/j.amjcard.2009.09.04","volume":"105","author":"D Aguilar","year":"2010","unstructured":"Aguilar D, Deswal A, Ramasubbu K, Mann DL, Bozkurt B (2010) Comparison of patients with heart failure and preserved left ventricular ejection fraction among those with versus without diabetes mellitus. Am J Cardiol 105:373\u2013377. https:\/\/doi.org\/10.1016\/j.amjcard.2009.09.04","journal-title":"Am J Cardiol"},{"key":"10186_CR20","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1093\/eurheartj\/ehn153","volume":"29","author":"MR MacDonald","year":"2008","unstructured":"MacDonald MR, Petrie MC, Varyani F, Ostergren J, Michelson EL, Young JB et al (2008) Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J 29:1377\u20131385. https:\/\/doi.org\/10.1093\/eurheartj\/ehn153","journal-title":"Eur Heart J"},{"key":"10186_CR21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1177\/1479164115579006","volume":"12","author":"CS Lam","year":"2015","unstructured":"Lam CS (2015) Diabetic cardiomyopathy: an expression of stage B heart failure with preserved ejection fraction. Diab Vasc Dis Res 12:234\u2013238. https:\/\/doi.org\/10.1177\/1479164115579006","journal-title":"Diab Vasc Dis Res"},{"key":"10186_CR22","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.107.7285","volume":"117","author":"L van Heerebeek","year":"2008","unstructured":"van Heerebeek L, Hamdani N, Handoko ML, Falcao-Pires I, Musters RJ, Kupreishvili K et al (2008) Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117:43\u201351. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.7285","journal-title":"Circulation"},{"key":"10186_CR23","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","volume":"30","author":"S Rubler","year":"1972","unstructured":"Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30:595\u2013602. https:\/\/doi.org\/10.1016\/0002-9149(72)90595-4","journal-title":"Am J Cardiol"},{"key":"10186_CR24","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/0002-9149(74)90089-7","volume":"34","author":"WB Kannel","year":"1974","unstructured":"Kannel WB, Hjortland M, Castelli WP (1974) Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34:29\u201334. https:\/\/doi.org\/10.1016\/0002-9149(74)90089-7","journal-title":"Am J Cardiol"},{"key":"10186_CR25","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1161\/hc4901.102568","volume":"104","author":"SA Hunt","year":"2001","unstructured":"Hunt SA, Baker DW, Chin MH, Cinquegrani MP, Feldman AM, Francis GS et al (2001) ACC\/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary circulation 104:2996\u20133007. https:\/\/doi.org\/10.1161\/hc4901.102568","journal-title":"ACC\/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary circulation"},{"key":"10186_CR26","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","volume":"122","author":"G Jia","year":"2018","unstructured":"Jia G, Hill MA, Sowers JR (2018) Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res 122:624\u2013638. https:\/\/doi.org\/10.1161\/CIRCRESAHA.117.311586","journal-title":"Circ Res"},{"key":"10186_CR27","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s10741-012-9313-3","volume":"18","author":"T Miki","year":"2013","unstructured":"Miki T, Yuda S, Kouzu H, Miura T (2013) Diabetic cardiomyopathy: pathophysiology and clinical features. Heart Fail Rev 18:149\u2013166. https:\/\/doi.org\/10.1007\/s10741-012-9313-3","journal-title":"Heart Fail Rev"},{"key":"10186_CR28","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jchf.2021.05.019","volume":"9","author":"M Packer","year":"2021","unstructured":"Packer M (2021) Differential pathophysiological mechanisms in heart failure with a reduced or preserved ejection fraction in diabetes. JACC Heart Fail 9:535\u2013549. https:\/\/doi.org\/10.1016\/j.jchf.2021.05.019","journal-title":"JACC Heart Fail"},{"issue":"11","key":"10186_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1475-2840-11-33.)","volume":"11","author":"R Anzawa","year":"2012","unstructured":"Anzawa R, Seki S, Nagoshi T, Taniguchi I, Feuvray D, Yoshimura M (2012) The role of Na+\/H+ exchanger in Ca2+ overload and ischemic myocardial damage in hearts from type 2 diabetic db\/db mice. Cardiovasc Diabetol 11(11):33. https:\/\/doi.org\/10.1186\/1475-2840-11-33.)","journal-title":"Cardiovasc Diabetol"},{"key":"10186_CR30","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1161\/CIRCRESAHA.108.175141","volume":"103","author":"TY Nakamura","year":"2008","unstructured":"Nakamura TY, Iwata Y, Arai Y, Komamura K, Wakabayashi S (2008) Activation of Na+\/H+ exchanger 1 is sufficient to generate Ca2+ signals that induce cardiac hypertrophy and heart failure. Circ Res 103:891\u2013899. https:\/\/doi.org\/10.1161\/CIRCRESAHA.108.175141","journal-title":"Circ Res"},{"key":"10186_CR31","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.amjmed.2019.08.027","volume":"133","author":"M Packer","year":"2020","unstructured":"Packer M (2020) Epicardial adipose tissue inflammation can cause the distinctive pattern of cardiovascular disorders seen in psoriasis. Am J Med 133:267\u2013272. https:\/\/doi.org\/10.1016\/j.amjmed.2019.08.027","journal-title":"Am J Med"},{"key":"10186_CR32","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.2174\/13816128113199990475","volume":"20","author":"K Fukami","year":"2014","unstructured":"Fukami K, Yamagishi S, Okuda S (2014) Role of AGEs-RAGE system in cardiovascular disease. Curr Pharm Des 20:2395\u20132402. https:\/\/doi.org\/10.2174\/13816128113199990475","journal-title":"Curr Pharm Des"},{"key":"10186_CR33","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4330\/wjc.v4.i4.90","volume":"4","author":"Z Hegab","year":"2012","unstructured":"Hegab Z, Gibbons S, Neyses L, Mamas MA (2012) Role of advanced glycation end products in cardiovascular disease. World J Cardiol 4:90\u2013102. https:\/\/doi.org\/10.4330\/wjc.v4.i4.90","journal-title":"World J Cardiol"},{"key":"10186_CR34","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1093\/eurheartj\/eht193","volume":"35","author":"TC Wong","year":"2014","unstructured":"Wong TC, Piehler KM, Kang IA, Kadakkal A, Kellman P, Schwartzman DS et al (2014) Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J 35:657\u2013664. https:\/\/doi.org\/10.1093\/eurheartj\/eht193","journal-title":"Eur Heart J"},{"key":"10186_CR35","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.2337\/diabetes.52.7.1825","volume":"52","author":"KR Bidasee","year":"2003","unstructured":"Bidasee KR, Nallani K, Yu Y, Cocklin RR, Zhang Y, Wang M et al (2003) Chronic diabetes increases advanced glycation end products on cardiac ryanodine receptors\/calcium-release channels. Diabetes 52:1825\u20131836. https:\/\/doi.org\/10.2337\/diabetes.52.7.1825","journal-title":"Diabetes"},{"key":"10186_CR36","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2337\/diabetes.53.2.463","volume":"53","author":"KR Bidasee","year":"2004","unstructured":"Bidasee KR, Zhang Y, Shao CH, Wang M, Patel KP, Dincer UD, Besch HR Jr (2004) Diabetes increases formation of advanced glycation end products on Sarco(endo)plasmic reticulum Ca2+-ATPase. Diabetes 53:463\u2013473. https:\/\/doi.org\/10.2337\/diabetes.53.2.463","journal-title":"Diabetes"},{"key":"10186_CR37","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1161\/01.RES.0000207406.94146.c2","volume":"98","author":"IG Poornima","year":"2006","unstructured":"Poornima IG, Parikh P, Shannon RP (2006) Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res 98:596\u2013605. https:\/\/doi.org\/10.1161\/01.RES.0000207406.94146.c2","journal-title":"Circ Res"},{"key":"10186_CR38","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s003950170057","volume":"96","author":"DX Zhang","year":"2001","unstructured":"Zhang DX, Fryer RM, Hsu AK, Zou AP, Gross GJ, Campbell WB, Li PL (2001) Production and metabolism of ceramide in normal and ischemic-reperfused myocardium of rats. Basic Res Cardiol 96:267\u2013274. https:\/\/doi.org\/10.1007\/s003950170057","journal-title":"Basic Res Cardiol"},{"key":"10186_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/eci.1357","volume":"3","author":"CA Ricciardi","year":"2021","unstructured":"Ricciardi CA, Gnudi L (2021) Vascular growth factors as potential new treatment in cardiorenal syndrome in diabetes. Eur J Clin Invest 3:e13579. https:\/\/doi.org\/10.1111\/eci.1357","journal-title":"Eur J Clin Invest"},{"key":"10186_CR40","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s12933-017-0615-6","volume":"16","author":"A Natali","year":"2017","unstructured":"Natali A, Nesti L, Fabiani I, Calogero E, Di Bello V (2017) Impact of empagliflozin on subclinical left ventricular dysfunctions and on the mechanisms involved in myocardial disease progression in type 2 diabetes: rationale and design of the EMPA-HEART trial. Cardiovasc Diabetol 16:130. https:\/\/doi.org\/10.1186\/s12933-017-0615-6","journal-title":"Cardiovasc Diabetol"},{"key":"10186_CR41","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/s10557-017-6734-1","volume":"3","author":"N Hammoudi","year":"2017","unstructured":"Hammoudi N, Jeong D, Singh R, Farhat A, Komajda M, Mayoux E et al (2017) Empagliflozin improves left ventricular diastolic dysfunction in a genetic model of type 2 diabetes. Cardiovasc Drugs Ther 3:233\u2013246. https:\/\/doi.org\/10.1007\/s10557-017-6734-1","journal-title":"Cardiovasc Drugs Ther"},{"key":"10186_CR42","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","volume":"140","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H et al (2019) Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial. Circulation 140:1693\u20131702. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.042375","journal-title":"Circulation"},{"key":"10186_CR43","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jcmg.2020.10.017","volume":"14","author":"T Mason","year":"2021","unstructured":"Mason T, Coelho-Filho OR, Verma S, Chowdhury B, Zuo F, Quan A et al (2021) Empagliflozin reduces myocardial extracellular volume in patients with type 2 diabetes and coronary artery disease. JACC Cardiovasc Imaging 14:1164\u20131173. https:\/\/doi.org\/10.1016\/j.jcmg.2020.10.017","journal-title":"JACC Cardiovasc Imaging"},{"key":"10186_CR44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jchf.2019.08.004","volume":"8","author":"J Li","year":"2020","unstructured":"Li J, Woodward M, Perkovic V, Figtree GA, Heerspink HJL, Mahaffey KW et al (2020) Mediators of the effects of Canagliflozin on heart failure in patients with type 2 diabetes. JACC Heart Fail 8:57\u201366. https:\/\/doi.org\/10.1016\/j.jchf.2019.08.004","journal-title":"JACC Heart Fail"},{"key":"10186_CR45","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s13300-019-00747-3","volume":"11","author":"DM Williams","year":"2020","unstructured":"Williams DM, Nawaz A, Evans M (2020) Renal outcomes in type 2 diabetes: a review of cardiovascular and renal outcome trials. Diabetes Ther 11:369\u2013386. https:\/\/doi.org\/10.1007\/s13300-019-00747-3","journal-title":"Diabetes Ther"},{"key":"10186_CR46","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.3389\/fphys.2018.0157","volume":"9","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Schumacher CA, Fiolet JWT, Kuschma MC, Hollmann MW et al (2018) Direct cardiac actions of sodium glucose cotransporter 2 inhibitors target pathogenic mechanisms underlying heart failure in diabetic patients. Front Physiol 9:1575. https:\/\/doi.org\/10.3389\/fphys.2018.0157","journal-title":"Front Physiol"},{"key":"10186_CR47","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.ijcard.2017.05.032","volume":"243","author":"A Di Franco","year":"2017","unstructured":"Di Franco A, Cantini G, Tani A, Coppini R, Zecchi-Orlandini S, Raimondi L et al (2017) Int J Cardiol 243:86\u201390. https:\/\/doi.org\/10.1016\/j.ijcard.2017.05.032","journal-title":"Int J Cardiol"},{"key":"10186_CR48","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.jacbts.2017.07.003","volume":"2","author":"NJ Byrne","year":"2017","unstructured":"Byrne NJ, Parajuli N, Levasseur JL, Boisvenue J, Beker DL, Masson G et al (2017) Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure. JACC Basic Transl Sci 2:347\u2013354. https:\/\/doi.org\/10.1016\/j.jacbts.2017.07.003","journal-title":"JACC Basic Transl Sci"},{"key":"10186_CR49","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/ejhf.1328","volume":"20","author":"S Pabel","year":"2018","unstructured":"Pabel S, Wagner S, Bollenberg H, Bengel P, Kov\u00e1cs \u00c1, Schach C et al (2018) Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail 20:1690\u20131700. https:\/\/doi.org\/10.1002\/ejhf.1328","journal-title":"Eur J Heart Fail"},{"key":"10186_CR50","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","volume":"13","author":"NJ Byrne","year":"2020","unstructured":"Byrne NJ, Matsumura N, Maayah ZH, Ferdaoussi M, Takahara S, Darwesh AM et al (2020) Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure. Circ Heart Fail 13:e006277. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.119.006277","journal-title":"Circ Heart Fail"},{"key":"10186_CR51","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1161\/CIRCULATIONAHA.121.053350","volume":"143","author":"K Philippaert","year":"2021","unstructured":"Philippaert K, Kalyaanamoorthy S, Fatehi M, Long W, Soni S, Byrne NJ, Barr A et al (2021) Circulation 143:2188\u20132204. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.053350","journal-title":"Circulation"},{"key":"10186_CR52","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.tcm.2015.05.006","volume":"26","author":"JC Makielski","year":"2016","unstructured":"Makielski JC (2016) Trends Cardiovasc Med 26:115\u2013122. https:\/\/doi.org\/10.1016\/j.tcm.2015.05.006","journal-title":"Trends Cardiovasc Med"},{"key":"10186_CR53","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","volume":"61","author":"L Uthman","year":"2018","unstructured":"Uthman L, Baartscheer A, Bleijlevens B, Schumacher CA, Fiolet JWT, Koeman A et al (2018) Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+\/H+ exchanger, lowering of cytosolic Na+ and vasodilation. Diabetologia 61:722\u2013726. https:\/\/doi.org\/10.1007\/s00125-017-4509-7","journal-title":"Diabetologia"},{"key":"10186_CR54","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1002\/ehf2.13024","volume":"7","author":"M Trum","year":"2020","unstructured":"Trum M, Riechel J, Lebek S, Pabel S, Sossalla ST, Hirt S (2020) ESC Heart Fail 7:4429\u20134437. https:\/\/doi.org\/10.1002\/ehf2.13024","journal-title":"ESC Heart Fail"},{"key":"10186_CR55","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1093\/cvr\/cvx186","volume":"114","author":"E D\u00edaz-Rodr\u00edguez","year":"2018","unstructured":"D\u00edaz-Rodr\u00edguez E, Agra RM, Fern\u00e1ndez \u00c1L, Adrio B, Garc\u00eda-Caballero T et al (2018) S.Effects of dapagliflozin on human epicardial adipose tissue: modulation of insulin resistance, inflammatory chemokine production, and differentiation ability. Cardiovasc Res 114:336\u2013346. https:\/\/doi.org\/10.1093\/cvr\/cvx186","journal-title":"Cardiovasc Res"},{"key":"10186_CR56","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.2337\/dc16-0330","volume":"39","author":"E Ferrannini","year":"2016","unstructured":"Ferrannini E, Mark M, Mayoux E (2016) CV Protection in the EMPA-REG OUTCOME ttrial: a \u201cthrifty substrate\u201d hypothesis. Diabetes Care 39:1108\u20131114. https:\/\/doi.org\/10.2337\/dc16-0330","journal-title":"Diabetes Care"},{"key":"10186_CR57","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1002\/ejhf.2131","volume":"23","author":"PM Becher","year":"2021","unstructured":"Becher PM, Schrage B, Ferrannini G, Benson L, Butler J, Carrero JJ et al (2021) Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry. Eur J Heart Fail 23:1012\u20131022. https:\/\/doi.org\/10.1002\/ejhf.2131","journal-title":"Eur J Heart Fail"},{"key":"10186_CR58","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1093\/eurheartj\/ehaa943","volume":"42","author":"WT Abraham","year":"2021","unstructured":"Abraham WT, Lindenfeld J, Ponikowski P, Agostoni P, Butler J, Desai AS et al (2021) Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes. Eur Heart J 42:700\u2013710. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa943","journal-title":"Eur Heart J"},{"key":"10186_CR59","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1161\/CIRCULATIONAHA.118.034222","volume":"138","author":"K R\u00e5dholm","year":"2018","unstructured":"R\u00e5dholm K, Figtree G, Perkovic V, Solomon SD, Mahaffey KW, de Zeeuw D et al (2018) Circulation 138:458\u2013468. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.118.034222","journal-title":"Circulation"},{"key":"10186_CR60","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ahj.2020.12.008","volume":"233","author":"A Sarraju","year":"2021","unstructured":"Sarraju A, Li J, Cannon CP, Chang TI, Agarwal R, Bakris G et al (2021) Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial. Am Heart 233:141\u2013148. https:\/\/doi.org\/10.1016\/j.ahj.2020.12.008","journal-title":"Am Heart"},{"key":"10186_CR61","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","volume":"139","author":"ET Kato","year":"2019","unstructured":"Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM et al (2019) Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation 139:2528\u20132536. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.040130","journal-title":"Circulation"},{"key":"10186_CR62","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1161\/CIRCULATIONAHA.120.05025","volume":"142","author":"F Cosentino","year":"2020","unstructured":"Cosentino F, Cannon CP, Cherney DZI, Masiukiewicz U, Pratley R, Dagogo-Jack S et al (2020) Efficacy of ertugliflozin on heart failure-related events in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease: results of the VERTIS CV trial. Circulation 142:2205\u20132215. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.120.05025","journal-title":"Circulation"},{"key":"10186_CR63","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","unstructured":"CONSENSUS Trial Study Group (1987) Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316:1429\u20131435. https:\/\/doi.org\/10.1056\/NEJM198706043162301","journal-title":"N Engl J Med"},{"key":"10186_CR64","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1111\/1753-0407.13182","volume":"13","author":"AK Singh","year":"2021","unstructured":"Singh AK, Singh R, Misra A (2021) Do SGLT-2 inhibitors exhibit similar cardiovascular benefit in patients with heart failure with reduced or preserved ejection fraction? J Diabetes 13:596\u2013600. https:\/\/doi.org\/10.1111\/1753-0407.13182","journal-title":"J Diabetes"},{"key":"10186_CR65","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/ejhf.1596","volume":"21","author":"SD Anker","year":"2019","unstructured":"Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J et al (2019) Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. Eur J Heart Fail 21:1279\u20131287. https:\/\/doi.org\/10.1002\/ejhf.1596","journal-title":"Eur J Heart Fail"},{"key":"10186_CR66","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1002\/ejhf.2064","volume":"22","author":"SD Anker","year":"2020","unstructured":"Anker SD, Butler J, Filippatos G, Shahzeb KM, Ferreira JP et al (2020) Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial. Eur J Heart Fail 22:2383\u20132392. https:\/\/doi.org\/10.1002\/ejhf.2064","journal-title":"Eur J Heart Fail"},{"key":"10186_CR67","doi-asserted-by":"publisher","unstructured":"Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, B\u00f6hm M et al (2021) Empagliflozin in heart failure with a\u00a0preserved\u00a0ejection fraction. N Engl J Med.\u00a0Online ahead of print.\u00a0https:\/\/doi.org\/10.1056\/NEJMoa2107038","DOI":"10.1056\/NEJMoa2107038"},{"key":"10186_CR68","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/results?cond=heart+failure+preserved&term=sglt2&cntry=&state=&city=&dist=. Accessed 16 July 2021"},{"key":"10186_CR69","doi-asserted-by":"publisher","unstructured":"Solomon SD, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN et al (2021) Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the\u00a0DELIVER\u00a0trial Eur J Heart Fail May 29.\u00a0Online ahead of print.\u00a0https:\/\/doi.org\/10.1002\/ejhf.2249","DOI":"10.1002\/ejhf.2249"}],"container-title":["Heart Failure Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-021-10186-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10741-021-10186-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10741-021-10186-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,27]],"date-time":"2023-04-27T07:07:29Z","timestamp":1682579249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10741-021-10186-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,1]]},"references-count":69,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["10186"],"URL":"https:\/\/doi.org\/10.1007\/s10741-021-10186-7","relation":{},"ISSN":["1573-7322"],"issn-type":[{"value":"1573-7322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,1]]},"assertion":[{"value":"25 October 2021","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2021","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}